Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation

14 May 2024

Abstract excerpt

Background Ataxia telangiectasia-mutated (ATM) kinase is a central regulator of the DNA damage response (DDR) signaling pathway, and its function is critical for the maintenance of genomic stability in cells that coordinate a network of cellular processes, including DNA replication, DNA repair, and cell cycle progression. ATM is frequently mutated in human cancers, and approximately 3% of lung cancers have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38807759
DOI: 10.3389/fonc.2024.1380633

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulationPMID 38807759Read ↗

Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations, and Homologous Recombination Deficiency (HRD)Semantic proximity Read ↗

ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung AdenocarcinomaSemantic proximity Read ↗

SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cellsSemantic proximity Read ↗

Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft ModelsSemantic proximity Read ↗

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP InhibitorsSemantic proximity Read ↗

DNA Damage Response Pathways in Tumor Suppression and Cancer TreatmentSemantic proximity Read ↗

Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.Semantic proximity Read ↗

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSemantic proximity Read ↗

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.Semantic proximity Read ↗

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.Semantic proximity Read ↗

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitorsSemantic proximity Read ↗

Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.